CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Agarwal, Neeraj, Azad, Arun, Carles, Joan, Matsubara, Nobuaki, Oudard, Stephane, Saad, Fred, Merseburger, Axel S., Soares, Andrey, McGregor, Bradley Alexander, Zurawski, Bogdan, North, Scott A., Tsiatas, Marinos, Bondarenko, Igor, Alfie, Margarita Sonia, Evilevitch, Lena, Sharma, Keerti, Nandoskar, Prachi, Ferraldeschi, Roberta, Wang, Fong, Pal, Sumanta Kumar
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article